Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongming Pan

Showing results (171-180 of 262) with videos related to

Pageof 27
Sort By:
Scientific Reports|August 18, 2017
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR statusHong Jian, Wei Li, Zhiyong Ma, et al.
BMC Cancer|December 24, 2017
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II studyRuihua Xu, Xianjun Yu, Jihui Hao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2020
A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid TumorsYong Fang, Fan Mo, Jiawei Shou, et al.
Cancer Cell International|January 30, 2021
Gene expression profiling for the diagnosis of multiple primary malignant tumorsYu Zheng, Yifeng Sun, Yue Kuai, et al.
Oncotarget|September 13, 2015
p53 controls colorectal cancer cell invasion by inhibiting the NF-κB-mediated activation of FascinXinbing Sui, Jing Zhu, Haimei Tang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE studyYi-Long Wu, Caicun Zhou, Shun Lu, et al.
Future Oncology (London, England)|March 31, 2022
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumorsYi-Long Wu, Ying Cheng, Huajun Chen, et al.
Eclinicalmedicine|August 20, 2025
Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trialZhi Peng, Ping Chen, Jin Lu, et al.
Scientific Reports|February 10, 2021
Retraction Note: JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagyXinbing Sui, Na Kong, Xian Wang, et al.
Pageof 27

Showing results (171-180 of 262) with videos related to

Sort By:
Pageof 27
Scientific Reports|August 18, 2017
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR statusHong Jian, Wei Li, Zhiyong Ma, et al.
BMC Cancer|December 24, 2017
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II studyRuihua Xu, Xianjun Yu, Jihui Hao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2020
A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid TumorsYong Fang, Fan Mo, Jiawei Shou, et al.
Cancer Cell International|January 30, 2021
Gene expression profiling for the diagnosis of multiple primary malignant tumorsYu Zheng, Yifeng Sun, Yue Kuai, et al.
Oncotarget|September 13, 2015
p53 controls colorectal cancer cell invasion by inhibiting the NF-κB-mediated activation of FascinXinbing Sui, Jing Zhu, Haimei Tang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE studyYi-Long Wu, Caicun Zhou, Shun Lu, et al.
Future Oncology (London, England)|March 31, 2022
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumorsYi-Long Wu, Ying Cheng, Huajun Chen, et al.
Eclinicalmedicine|August 20, 2025
Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trialZhi Peng, Ping Chen, Jin Lu, et al.
Scientific Reports|February 10, 2021
Retraction Note: JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagyXinbing Sui, Na Kong, Xian Wang, et al.
Pageof 27